EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Sorafenib: advances in targeted therapy for renal cell carcinoma

Robert E Hawkins, Fiona C Thistlethwaite

Future Prescriber · 2006

DOI: 10.1002/fps.12 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract Sorafenib is the first dual action oral multi‐kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →